欧洲65岁以上成人侵袭性肺炎球菌疾病血清型发病率及疫苗覆盖比较
该研究综合2011至2023年欧洲15国监测数据,比较≥65岁成人侵袭性肺炎球菌疾病(IPD)中PCV21与PCV20可覆盖血清型的比例。结果显示PCV21可靶向比例持续上升,2014年起超过PCV20,至2023年总体血清型覆盖率差异达14.0%。结论提示在成人肺炎球菌疫苗接种规划中引入PCV21可能有助于减轻该高风险人群的疾病负担。
要点
- 2014年起,≥65岁成人IPD中PCV21可靶向血清型比例超过PCV20。
- 至2023年,PCV21与PCV20的总体血清型覆盖率差异为14.0%。
- 该趋势主要由2011–2019年IPD报告发病率较高的8个国家驱动。
核心结论
- 在许多欧洲国家,≥65岁成人IPD中PCV21可靶向血清型所致病例已多于PCV20可靶向血清型。
- 在成人肺炎球菌疫苗接种规划中引入PCV21可能有助于减轻该高风险年龄组的IPD临床和经济负担。
研究设计与样本
- 研究综合了2011至2023年年龄和血清型特异性IPD发病率数据。
- 数据来源于政府监测报告和同行评议出版物。
- 连续血清型特异性IPD发病率数据覆盖15个欧洲国家。
主要发现
- 研究期间,≥65岁成人IPD中PCV21可靶向病例的平均比例上升。
- 2014年起,PCV21可靶向比例超过PCV20可靶向比例。
- 至2023年,PCV21与PCV20的总体血清型覆盖率差异为14.0%。
- 上述趋势主要由2011至2019年IPD报告发病率显著高于其他7国的8个国家驱动。
临床怎么用
- 在≥65岁成人肺炎球菌疫苗接种规划中,可考虑PCV21以覆盖更多当前流行血清型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive pneumococcal disease (IPD) is associated with a significant clinical and economic burden among adults ≥65 years of age in Europe. The distribution of bacterial serotypes responsible for IPD has changed over time, including in response to the introduction of pediatric and adult pneumococcal conjugate vaccines (PCVs). These shifts necessitate the ongoing development of new multivalent vaccines to ensure that pneumococcal vaccination programs continue to target serotypes associated with significant disease burden. OBJECTIVE: The aim of the current study was to compare the proportion of IPD cases among adults ≥65 years of age that are targetable with PCV21 compared to PCV20 in multiple European countries, and to assess trends in these proportions over time. METHODS: We synthesized age- and serotype-specific IPD incidence data from 2011 to 2023. Data were obtained from government surveillance reports and peer-reviewed publications. RESULTS: Continuous serotype-specific data on the incidence of IPD among adults ≥65 years of age were available for 15 European countries. The average proportion of these IPD cases that were targetable by PCV21 increased during the study period; from 2014 onward, this proportion exceeded the proportion of cases targetable by PCV20, with an overall difference in serotype coverage of 14.0 % by 2023. These trends were driven largely by 8 countries that had a markedly higher reported incidence of IPD between 2011 and 2019 compared to the other 7 countries. CONCLUSIONS: In many European countries, PCV21-targetable serotypes are now responsible for more cases of IPD among adults ≥65 years of age than are PCV20-targetable serotypes. Implementing PCV21 in adult pneumococcal vaccination programs may therefore help reduce the clinical and economic burden of IPD among this high-risk age group.
引用
- Floros L, Johnson KD, Tsoumani E, et al. Serotype-specific incidence and comparative vaccine coverage of invasive pneumococcal disease among adults ≥65 years of age in European countries from 2011 to 2023. Vaccine. 2026. PMID: 41564841. doi:10.1016/j.vaccine.2025.128181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。